<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633683</url>
  </required_header>
  <id_info>
    <org_study_id>XP110</org_study_id>
    <nct_id>NCT02633683</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS</brief_title>
  <acronym>RLS</acronym>
  <official_title>A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XenoPort, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XenoPort, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT&#xD;
      (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years&#xD;
      of age) diagnosed with moderate-to-severe primary RLS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete the 12-week daily dosing efficacy and safety study (XP109) will be&#xD;
      allowed to enroll in the open-label extension (OLE) study (XP110), thereby providing exposure&#xD;
      to HORIZANT for up to 48 weeks. Enrolled patients will take open-label HORIZANT 600 mg&#xD;
      tablets once a day at approximately 5 PM with food, beginning at Week 0 of the OLE study up&#xD;
      to and including Week 36. After the end of the treatment period, a follow-up visit will be&#xD;
      included 14 days (± 3 days) after the last dose of HORIZANT. Patients will visit the clinical&#xD;
      site on 6 different occasions, including a follow-up visit 14 days (± 3 days) after the last&#xD;
      dose of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score</measure>
    <time_frame>Week 12</time_frame>
    <description>assessment at designated timepoints</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>RLS</condition>
  <arm_group>
    <arm_group_label>HORIZANT 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HORIZANT 600 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HORIZANT 600 mg</intervention_name>
    <description>HORIZANT 600 mg once daily</description>
    <arm_group_label>HORIZANT 600 mg</arm_group_label>
    <other_name>Gabapentin Enacarbil Extended-Release Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who completed participation in HORIZANT Study XP109.&#xD;
&#xD;
          -  Negative pregnancy test for females of childbearing potential. Male patients able to&#xD;
             father a child must agree to use a barrier method (male condom, female condom,&#xD;
             diaphragm, or cervical cap) with spermicide for at least 30 days prior to dosing and&#xD;
             throughout the study. Fertile, sexually active patients must agree to use 2 medically&#xD;
             accepted methods of contraception&#xD;
&#xD;
          -  Patients must be willing to refrain from using any drugs that are likely to affect RLS&#xD;
             or sleep assessments for the duration of the study.&#xD;
&#xD;
          -  Signed patient and parent (or legal guardian) Institutional Review Board&#xD;
             (IRB)-approved assent and consent forms before any study procedures are carried out&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, would be noncompliant with the study&#xD;
             visit schedule, procedures, or medication administration&#xD;
&#xD;
          -  Patients who have developed clinically significant or unstable medical conditions, or&#xD;
             who would otherwise be unsuitable for participation in a continuation study with&#xD;
             gabapentin enacarbil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Caras, MD</last_name>
    <role>Study Director</role>
    <affiliation>Xenoport/Arbor Pharmaceuticals, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Alexander</last_name>
    <phone>520-252-1908</phone>
    <email>Camilla.Alexander@wwctrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Sleep Medicine Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dixie Creager</last_name>
      <phone>619-294-4302</phone>
      <email>dcreager@prnsd.com</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Jjirk</last_name>
      <phone>619-294-4302</phone>
      <email>jjirik@prnsd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Thein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Pediatric Research Institute</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Patenaude</last_name>
      <phone>407-898-2767</phone>
      <phone_ext>240</phone_ext>
      <email>heidi@ajayihealthcare.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Simonian</last_name>
      <phone>407-898-2767</phone>
      <phone_ext>140</phone_ext>
      <email>sarah@ajayihealthcare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Akinyemi Ajayi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta, INC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Mann</last_name>
      <phone>317-537-6088</phone>
      <phone_ext>1229</phone_ext>
      <email>kcleveland@jwmneuro.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Cleveland</last_name>
      <phone>317-806-6965</phone>
      <email>kcleveland@jwmneuro.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ridel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mercy Health - Children's Hospital Pulmonary &amp; Sleep Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Sleep Center at the Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>SleepMed of South Carolina; SleepMed, Inc.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Scallon, CRC</last_name>
      <phone>803-251-1093</phone>
      <email>nscallon@sleepmedinc.com</email>
    </contact>
    <investigator>
      <last_name>Richard Bogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restless Legs Syndrome</keyword>
  <keyword>RLS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

